The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

Controlled Trial ◽

Newly Diagnosed ◽

Open Label ◽

Multicentre Phase ◽

The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(21)00247-6 ◽

2021 ◽

Vol 397 (10282) ◽

pp. 1363-1374 ◽

Cited By ~ 1

Author(s):

Anthony Marson ◽

Girvan Burnside ◽

Richard Appleton ◽

Dave Smith ◽

John Paul Leach ◽

...

Keyword(s):

Cost Effectiveness ◽

Focal Epilepsy ◽

Controlled Trial ◽

Newly Diagnosed ◽

Open Label ◽

Multicentre Phase ◽

Faculty Opinions recommendation of The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.739920891.793585363 ◽

2021 ◽

Author(s):

Adam Hartman

Keyword(s):

Cost Effectiveness ◽

Controlled Trial ◽

Newly Diagnosed ◽

Open Label ◽

Multicentre Phase ◽

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00362-9 ◽

2015 ◽

Vol 16 (16) ◽

pp. 1691-1699 ◽

Cited By ~ 191

Author(s):

Christoph Röllig ◽

Hubert Serve ◽

Andreas Hüttmann ◽

Richard Noppeney ◽

Carsten Müller-Tidow ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Standard Therapy ◽

Controlled Trial ◽

Phase 2 ◽

Newly Diagnosed ◽

Multicentre Phase ◽

Randomised Controlled ◽

Acute Myeloid

Impact of nicotine replacement therapy as an adjunct to anti-tuberculosis treatment and behaviour change counselling in newly diagnosed pulmonary tuberculosis patients: an open-label, randomised controlled trial

Scientific Reports ◽

10.1038/s41598-018-26990-5 ◽

2018 ◽

Vol 8 (1) ◽

Cited By ~ 4

Author(s):

Surendra Kumar Sharma ◽

Alladi Mohan ◽

Achintya Dinesh Singh ◽

Hridesh Mishra ◽

Sonali Jhanjee ◽

...

Keyword(s):

Pulmonary Tuberculosis ◽

Replacement Therapy ◽

Nicotine Replacement Therapy ◽

Controlled Trial ◽

Newly Diagnosed ◽

Open Label ◽

Tuberculosis Patients ◽

Behaviour Change Counselling ◽

Effectiveness and Cost-Effectiveness of Adjunctive Personalised Psychosocial Intervention in Treatment-Resistant Opioid Agonist Therapy: A Pragmatic, Open-Label, Randomised Controlled Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3223117 ◽

2018 ◽

Author(s):

John Marsden ◽

Garry Stillwell ◽

Kirsty James ◽

James Shearer ◽

Sarah Byford ◽

...

Keyword(s):

Cost Effectiveness ◽

Psychosocial Intervention ◽

Controlled Trial ◽

Treatment Resistant ◽

Agonist Therapy ◽

Open Label ◽

Opioid Agonist ◽

Opioid Agonist Therapy ◽

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30404-7 ◽

2017 ◽

Vol 18 (7) ◽

pp. 929-945 ◽

Cited By ~ 29

Author(s):

David Cameron ◽

James P Morden ◽

Peter Canney ◽

Galina Velikova ◽

Robert Coleman ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Therapy ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Multicentre Phase ◽

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30452-6 ◽

2020 ◽

Vol 21 (10) ◽

pp. 1317-1330 ◽

Cited By ~ 3

Author(s):

Shaji K Kumar ◽

Susanna J Jacobus ◽

Adam D Cohen ◽

Matthias Weiss ◽

Natalie Callander ◽

...

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

Stem Cell Transplantation ◽

Controlled Trial ◽

Newly Diagnosed ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

REpeated AutoLogous Infusions of STem cells In Cirrhosis (REALISTIC): a multicentre, phase II, open-label, randomised controlled trial of repeated autologous infusions of granulocyte colony-stimulating factor (GCSF) mobilised CD133+ bone marrow stem cells in patients with cirrhosis. A study protocol for a randomised controlled trial

BMJ Open ◽

10.1136/bmjopen-2015-007700 ◽

2015 ◽

Vol 5 (3) ◽

pp. e007700-e007700 ◽

Cited By ~ 18

Author(s):

A. King ◽

D. Barton ◽

H. A. Beard ◽

N. Than ◽

J. Moore ◽

...

Keyword(s):

Stem Cells ◽

Bone Marrow ◽

Controlled Trial ◽

Granulocyte Colony Stimulating Factor ◽

Colony Stimulating Factor ◽

Open Label ◽

Multicentre Phase ◽

Randomised Controlled ◽

Stimulating Factor

A Multicentre, Phase II, Open-Label, Randomised Controlled Trial of Repeated Autologous Infusions of Granulocyte Colony Stimulating Factor Mobilised Cd133 + Bone Marrow Stem Cells in Patients with Cirrhosis

Journal of Hepatology ◽

10.1016/s0168-8278(16)01695-0 ◽

2016 ◽

Vol 64 (2) ◽

pp. S183-S184 ◽

Cited By ~ 1

Author(s):

P.N. Newsome ◽

R. Fox ◽

A. King ◽

N. Than ◽

J. Moore ◽

...

Keyword(s):

Stem Cells ◽

Bone Marrow ◽

Controlled Trial ◽

Granulocyte Colony Stimulating Factor ◽

Colony Stimulating Factor ◽

Open Label ◽

Multicentre Phase ◽

Randomised Controlled ◽

Stimulating Factor

Investigating the cost-effectiveness of videotelephone based support for newly diagnosed paediatric oncology patients and their families: design of a randomised controlled trial

BMC Health Services Research ◽

10.1186/1472-6963-7-38 ◽

2007 ◽

Vol 7 (1) ◽

Cited By ~ 21

Author(s):

Mark Bensink ◽

Richard Wootton ◽

Helen Irving ◽

Andrew Hallahan ◽

Deborah Theodoros ◽

...

Keyword(s):

Cost Effectiveness ◽

Controlled Trial ◽

Paediatric Oncology ◽

Newly Diagnosed ◽

Oncology Patients ◽

Randomised Controlled ◽

The Cost